HALEOS LABS financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹72.9cr−11.6% on Q1 FY26
Net profit
₹1.8cr−58.0% on Q1 FY26
EBITDA margin
12.5%−1.7 pts on Q1 FY26
EPS
₹8.75−36.4% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue72.982.5−11.6%
EBITDA9.111.7−22.1%
EBITDA margin12.5%14.2%−1.7 pts
Profit before tax3.47.0−51.0%
Net profit1.84.4−58.0%
EPS₹8.75₹13.75−36.4%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹72.9 crNet profit₹1.8 crNet margin2.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
439————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.21.20.50.61.3
16.016.015.516.819.6
10910984.097.798.6
562————
324334345306316
—−3.2%+12.7%−3.0%—
40.944.745.031.128.8
12.6%13.4%13.1%10.2%9.1%
25.029.230.016.218.0
15.317.818.76.311.4
4.7%5.3%5.4%2.1%3.6%
₹52.27₹57.26₹66.51₹30.08₹37.92
—−13.9%+121.2%−20.7%—
—37.234.124.314.7
—−57.9−15.3−20.9−48.6
−20.6−20.618.73.4−33.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HALEOSLABS₹1,450.60

HALEOS LABS LIMITED

· Pharma & Health
₹ CrorePeersALBERTDAVDVALIANTLABMEDICOMEDICAMEQZIMLABAAREYDRUGSNECLIFEANUHPHRMcap ₹439 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————438.6
- Cash, Equiv & ST Investments1.30.60.51.21.2
+ Minority Interest19.616.815.516.016.0
+ Total Debt98.697.784.0108.9108.9
Enterprise Value————562.2
Revenue315.6306.0344.7333.8324.2
Growth %, YoY—-3.0+12.7-3.2—
EBITDA28.831.145.044.740.9
Margin %9.1110.1713.0713.3812.61
EBIT18.016.230.029.225.0
Net Income11.46.318.717.815.3
Margin %3.612.075.435.334.71
EPS, Adj (current shares)37.9230.0866.5157.2652.27
Growth %, YoY—-20.7+121.2-13.9—
Cash from Operations14.724.334.137.2—
Capital Expenditures-48.6-20.9-15.3-57.9—
Free Cash Flow-33.93.418.7-20.6-20.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

HALEOS LABS financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

HALEOS LABS (NSE: HALEOSLABS) had a market capitalisation of ₹432 crore at the 29 October 2026 close (₹1,429.20 a share), a PE ratio of 27.3 on the last four quarters' profit and a price-to-book ratio of 2.02. In FY26 its consolidated net profit attributable to shareholders was ₹17.3 crore on revenue of ₹334 crore; in Q1 FY27 (April–June 2026) it was ₹2.6 crore, down 36.3% year on year. Its debt-to-equity ratio was 0.47 on 31 March 2026. Promoters held 72.11% of the shares on 30 September 2026.

HALEOS LABS Q1 FY27 results
filed 5 August 2026
Share price used
₹1,429.20 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

HALEOS LABS at a glance · consolidated

Market cap
₹432 Crat ₹1,429.20 · 29 Oct close
PE ratio (last 4 quarters)
27.325.0 on FY26 profit
Price to book (PB)
2.02book value ₹706.34 a share
ROE (FY26)
8.4%−2.3 pts vs FY25ROCE 10.7%
Debt to equity
0.47net debt ₹106 Cr
Promoter holding
72.11%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.10%₹1.50 a share in 12 months
Net worth
₹214 Cr+8.6% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹20.6 Cr

Questions

What is the HALEOS LABS PE ratio today?

HALEOS LABS's PE ratio is 27.3 at the 29 October 2026 close (₹1,429.20 a share): a market capitalisation of ₹432 crore divided by consolidated net profit attributable to shareholders of ₹15.8 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹17.3 crore) it is 25.0.

What is the HALEOS LABS PB ratio (price to book value)?

HALEOS LABS's price-to-book (PB) ratio is 2.02 at the 29 October 2026 close: a market capitalisation of ₹432 crore divided by shareholders' equity (book value) of ₹214 crore on 31 March 2026. That is a book value of ₹706.34 per share against a share price of ₹1,429.20.

What is the HALEOS LABS net worth?

HALEOS LABS's net worth — shareholders' equity in its consolidated balance sheet — was ₹214 crore on 31 March 2026, up 8.6% from ₹197 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹432 crore at the 29 October 2026 close.

What is the HALEOS LABS market cap?

HALEOS LABS's market capitalisation was ₹432 crore at the 29 October 2026 close: 30.23 lakh shares at ₹1,429.20 each.

What is the HALEOS LABS EPS?

HALEOS LABS's basic earnings per share (EPS) were ₹57.26 in FY26, against ₹66.51 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹52.27.

What is the HALEOS LABS dividend in 2026 and its record date?

In 2026, HALEOS LABS has declared one dividend: ₹1.50 with record date 23 September 2026.

Is HALEOS LABS debt free?

No. HALEOS LABS had borrowings of ₹109 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.47. Its cash and current investments were ₹2.4 crore, so its net debt was ₹106 crore.

What is the HALEOS LABS debt to equity ratio?

HALEOS LABS's debt-to-equity ratio was 0.47 on 31 March 2026: borrowings of ₹109 crore against total equity of ₹230 crore. A year earlier, on 31 March 2025, it was 0.40.

What is the HALEOS LABS promoter holding?

Promoters held 72.11% of HALEOS LABS on 30 September 2026, unchanged from the previous quarter and up 0.70 percentage points from 71.41% a year earlier, according to the shareholding pattern filed with NSE.

What is the HALEOS LABS ROE and ROCE?

In FY26, HALEOS LABS's return on equity (ROE) was 8.4% and its return on capital employed (ROCE) was 10.7%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 10.8% and ROCE 12.2%.

What are the HALEOS LABS latest quarterly results?

HALEOS LABS's latest results are for Q1 FY27 (April–June 2026), filed on 5 August 2026: consolidated net profit attributable to shareholders ₹2.6 crore, down 36.3% from ₹4.2 crore in Q1 FY26; revenue from operations ₹72.9 crore, down 11.6% year on year.

What is the HALEOS LABS revenue and profit in FY26?

In FY26 (April 2025–March 2026), HALEOS LABS's consolidated net profit attributable to shareholders was ₹17.3 crore, down 13.9% from ₹20.1 crore in FY25, on revenue from operations of ₹334 crore (down 3.2%). Over three years, from FY23, net profit was up 51.0%.

What is the HALEOS LABS book value per share?

HALEOS LABS's book value per share was ₹706.34 on 31 March 2026: shareholders' equity of ₹214 crore divided by the 30.23 lakh shares in issue, up 8.6% from ₹650.15 a year earlier. The share price at the 29 October 2026 close was ₹1,429.20.

What is the HALEOS LABS dividend yield?

HALEOS LABS's dividend yield is 0.10% at the 29 October 2026 close: dividends of ₹1.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,429.20. They were ₹1.50 on 23 September 2026.

What is the HALEOS LABS shareholding pattern?

On 30 September 2026, HALEOS LABS's shares were held by promoters 72.11%, domestic institutions (DII) 0.31% and retail and other non-institutional investors 27.58%. Over the year, DII holding was up 0.28 percentage points from 0.03%.

What is the HALEOS LABS free cash flow?

In FY26, HALEOS LABS generated ₹37.2 crore of cash from operations and spent ₹57.9 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹20.6 crore. In FY25 it was ₹18.7 crore.

When are the HALEOS LABS next results?

HALEOS LABS has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does HALEOS LABS compare with its peers?

On FY26 consolidated figures, against Albert David, Valiant Laboratories and Medico Remedies: HALEOS LABS's operating margin of 8.8% is the highest of the four (Albert David −1.3%, Valiant Laboratories 0.2%, Medico Remedies 6.8%; peer average 1.9%); its return on equity of 8.4% is the second highest of the four (Albert David −0.4%, Valiant Laboratories −1.2%, Medico Remedies 19.0%; peer average 5.8%).

HALEOS LABS vs Albert David: how do they compare?

In FY26, HALEOS LABS earned net profit attributable to shareholders of ₹17.3 crore on revenue of ₹334 crore, against ₹1.5 crore on ₹334 crore for Albert David. HALEOS LABS's operating margin was 8.8% (Albert David −1.3%) and its return on equity 8.4% (Albert David −0.4%). At the 29 October 2026 close, HALEOS LABS's market capitalisation was ₹432 crore against ₹438 crore for Albert David.

Where do these HALEOS LABS figures come from?

From HALEOS LABS's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.